Maxim Affirms BiolineRx (BLRX) at 'Buy'; BL-8040 Should be Focus for Immune Oncology Segment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Maxim Affirms BiolineRx (BLRX) at 'Buy'; BL-8040 Should be Focus for Immune Oncology Segment

BioLineRx (BLRX) Tops Q3 EPS by 6c

November 16, 2015 8:34 AM EST

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.02), $0.06 better than the analyst estimate of ($0.08).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

... More